Human Genome

(

HGSI

) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 1.6%. By the end of trading, Human Genome fell 26 cents (-1.9%) to $13.62 on average volume. Throughout the day, 6.7 million shares of Human Genome exchanged hands as compared to its average daily volume of eight million shares. The stock ranged in price between $13.41-$13.83 after having opened the day at $13.78 as compared to the previous trading day's close of $13.88. Other company's within the Drugs industry that declined today were:

MediciNova

(

MNOV

), down 42.9%,

Catalyst Pharmaceutical Partners

(

CPRX

), down 34.5%,

Senesco Technologies

(

SNT

), down 9.3%, and

PROLOR Biotech

(

PBTH

), down 5.9%.

Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. Its principal products include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. Human Genome has a market cap of $2.79 billion and is part of the

health care

sector. Shares are up 87.8% year to date as of the close of trading on Wednesday. Currently there are eight analysts that rate Human Genome a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Human Genome as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and generally weak debt management.

On the positive front,

Vermillion

(

VRML

), up 47.9%,

Rosetta Genomics

(

ROSG

), up 44.9%,

Telik

(

TELK

), up 29.8%, and

ARCA biopharma

(

ABIO

), up 27%, were all gainers within the drugs industry with

Merck

(

MRK

) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null